Cristina Arias / Cover / Getty Images Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive ...

Roche is stepping into the hot weight-loss drug market currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). The Swiss pharmaceutical company has entered into an exclusive agreement with ...

Its strategy focuses on expanding its drug portfolio, advancing precision medicine, and addressing unmet medical needs. Eli Lilly and Company (NYSE:LLY) has several significant pipeline catalysts ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid ... delaying its review of the drug. Lilly said the US regulator “wants ...

The weight loss potential is not exactly there to match the likes of Eli Lilly’s tirzepatide or Novo Nordisk’s CagriSema which has an amylin analog as a “performance enhancer” on top of ...

Eli Lilly has opted to end a phase 2 rheumatoid arthritis (RA) trial of a drug it is developing with Korea’s Hanmi Pharmaceuticals, according to press reports. The Korea Biomedical Review cited ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...